6th Russian-Swedish Economic Forum 2016 "New investment potential: ideas and opportunities"

24 November 2016, Lidingö, Sweden.
Russia has set a course for supporting the latest scientific research and, in particular, on drugs, and transferring the new technologies to Western markets. One example of such developments is the project by the Biomedical Centre of St. Petersburg, led by Professor Andrey Kozlov. This private think tank researches the role of epidemiological approaches to the fight against HIV and AIDS, develops new concepts of active preventative measures and has been working on a vaccine against the virus since 1994. Some of the potential vaccines developed at the Centre have successfully passed their pre-clinical and clinical trials and are now awaiting state support for conducting the 2nd and 3rd phases of the clinical trials.

The Science Magazine has praised the Biomedical Centre of St. Petersburg as an 'island of talented investigators' for their contribution to 'clarifying the rate of spread of HIV among injecting drug users and documenting the transmission from IDUs into the broader population through heterosexual sex'. The magazine said that Russian scientists arrived at the very epicentre of research on vaccines against HIV and that the importance of their work goes far beyond the Russian borders.

The initiative put forward by the Industry and Trade Ministry in 2016 was aimed at helping such promising innovative developments to enter the market. This initiative has seen the launch of a programme for promoting, expert trials, analytical support and business acceleration for research projects which have earlier received state funding.

The programme was designed to support the development of successful research, reassess the projects' viability and patentability, and to analyse their technological and economic potential for scaling both in Russia and abroad.

The selection process involved assessment by a number of experts from a variety of fields, such as medicine, pharmaceuticals, innovations and intellectual property, as well as representatives of the business. Projects were reviewed by representatives of both the scientific and the methodological schools. Such an approach ensured a comprehensive assessment and eliminated any risk of a conflict of interests; one of the prerequisites for being an expert was having no connection to any of the participants of this project.

Such efforts to ensure independent assessment have been made as the Ministry aims to commercialise new technologies based on original ideas and latest developments on global markets as soon as possible. Russian drugs get approved by foreign investors who recognise their competitiveness with increasing frequency. Similarly, the global financial crisis and the rouble's devaluation against other currencies over the past few years have made the environment for joint projects in Russia more attractive and have worked in favour of such international syndicates.

The programme of the 6th Russian-Swedish economic forum on new investment potential, which will take place in Stockholm, includes a presentation of the project office and Russian innovative projects in pharmaceuticals and biotechnologies on 24 November.

In 2017 the Ministry of Industry and Trade of the Russian Federation is planning to expand the work of the independent project reviewing commission.

For further information about the 6th Russian-Swedish economic forum, please visit:
http://rysslandshandel.se/en/vi-russian-swedish-economic-forum-2016/

You can register for the 6th Russian-Swedish economic forum here: http://rysslandshandel.se/forum/forum2016_registration.php

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]